2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections

Antiviral Research

Volumn 55, Issue 3, 2002, Pages 413-424

  Snoeck, Robert ^a   Andrei, Graciela ^a   Bodaghi, Bahram ^b   Lagneaux, Laurence ^c   Daelemans, Dirk ^a   De Clercq, Erik ^a   Neyts, Johan ^a   Schols, Dominique ^a   Naesens, Lieve ^a   Michelson, Susan ^d   Bron, Dominique ^c   Otto, Michael J ^e   Bousseau, Anne ^e   Nemecek, Conception ^e   Roy, Christine ^e  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d INSTITUT PASTEUR   (France)

^e SANOFI   (France)

Author keywords

CMV423; Human cytomegalovirus; Immediate early antigens

Indexed keywords

2 CHLORO 3 PYRIDIN 3 YL 5,6,7,8 TETRAHYDROINDOLIZINE 1 CARBOXAMIDE; ANTIVIRUS AGENT; CIDOFOVIR; CMV 423; DNA POLYMERASE; FOSCARNET SODIUM; GANCICLOVIR; IMMEDIATE EARLY PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW CELL; CELL ASSAY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; BONE MARROW CELLS; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; DNA REPLICATION; DNA, VIRAL; DRUG THERAPY, COMBINATION; GANCICLOVIR; HUMANS; INDOLIZINES; PIGMENT EPITHELIUM OF EYE; PYRIDINES;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 18644374841     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00074-8     Document Type: Article

References (32)

1. Abraham B., Lastere S., Reynes J., Bibollet-Ruche F., Vidal N., Segondy M. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates with AIDS treated with ganciclovir. J. Clin. Virol. 13:1999;141-148.
2. Andrei G., Snoeck R., Schols D., Goubau P., Desmyter J., De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;1026-1033.
3. Andrei G., Snoeck R., Goubau P., Desmyter J., De Clercq E. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;143-151.
4. Andrei G., Snoeck R., Reymen D., Liesnard C., Goubau P., Desmyter J., De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur. J. Clin. Microbiol. Infect. Dis. 14:1995;318-329.
5. Boulware S.L., Bronstein J.C., Nordby E.C., Weber P.C. Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res. 51:2001;111-125.
6. Chrisp P., Clissold S.P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 41:1991;104-129.
7. Eddleston M., Peacock S., Juniper M., Warrell D.A. Severe cytomgalovirus infection in immunocompetent patients. Clin. Infect. Dis. 24:1997;52-56.
8. Grundy J.E. Current antiviral therapy fails to prevent the pro-inflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack. Scholz M., Rabeneau H.F., Doerr H.W., Cinatl J. Jr, . CMV-Related Immunopathology. Monographs in Virology. 1998;67-89 Karger, Basel.
9. Hebart H., Kanz L., Jahn G., Einsele H. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs. 55:1998;59-72.
10. Humar A., St. Louis P., Mazzulli T., McGeer A., Lipton J., Messner H., MacDonald K.S. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. J. Infect. Dis. 179:1999;484-488.
11. Jacobson J.G., Renau T.E., Nassiri M.R., Sweier D.G., Breitenbach J.M., Townsend L.B., Drach J.C. Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus. Antimicrob. Agents Chemother. 43:1999;1888-1894.
12. Lagneaux L., Delforge A., Snoeck R., Bosmans E., Moreau J.F., Taupin J.L., De Clercq E., Stryckmans P., Bron D. Human cytomegalovirus increases constitutive production of interleukin-6 and leukemia inhibitory factor by bone marrow stromal cells. Blood. 87:1996;59-66.
13. Lagneaux L., Delforge A., Snoeck R., Bosmans E., Schols D., De Clercq E., Stryckmans P., Bron D. Imbalance in production of cytokines by bone marrow stromal cells following cytomegalovirus infection. J. Infect. Dis. 174:1996;913-919.
14. Littler E., Stuart A.D., Chee M.S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 358:1992;160-162.
15. Lurain N.S., Spafford L.E., Thompson K.D. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:1994;4427-4431.
16. Miceli M.V., Newsome D.A., Novak L.C., Beuerman R.W. Cytomegalovirus replication in cultured human retinal pigment epithelial cells. Curr. Eye Res. 8:1989;835-839.
17. Murayama T., Ohara Y., Obuchi M., Khabar K.S., Higashi H., Mukaida N., Matsushima K. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-kappaB-binding sites of the interleukin-8 gene. J. Virol. 71:1997;5692-5695.
18. Naesens L., Snoeck R., Andrei G., Balzarini J., Neyts J., De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8:1997;1-23.
19. Neyts J., Andrei G., Snoeck R., Meerbach A., De Clercq E. Methods in anti-HCMV research. Sinclair J., Cytomegalovirus Protocols. 2000;129-152 Humana Press, Totowa, NJ.
20. Neyts J., Naesens L., Ying C., De Bolle L., De Clercq E. Anti-herpesvirus activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)-cycloprop- 1′-yl]methyl]. Antiviral Res. 49:2001;115-120.
21. Noble S., Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 56:1998;115-146.
22. Penfold M.E., Dairaghi D.J., Duke G.M., Saederup N., Mocarski E.S., Kemble G.W., Schall T.J. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. USA. 96:1999;9839-9844.
23. Reddy V., Hao Y., Lipton J., Meharchand J., Minden M., Mazzulli T., Chan C., Messner H.A. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy. J. Clin. Virol. 13:1999;149-159.
24. Snoeck R., Sakuma T., De Clercq E., Rosenberg I., Holý A. (S)-1(3-Hydroxy-2-Phosphonylmethoxyprophyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1988;1839-1844.
25. Snoeck R., Andrei G., Schols D., Balzarini J., De Clercq E. Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;1144-1155.
26. Snoeck, R., Andrei, G., De Clercq, E. 1996. Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. Eur. J. Clin. Microbiol. Infect. Dis. July 15(7), 574-579.
27. Sullivan V., Biron K.K., Talarico C., Stanat S.C., Davis M., Pozzi L.M., Coen D.M. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:1993;19-25.
28. Sweet C. The pathogenicity of cytomegalovirus. FEMS Microbiol. Rev. 23:1999;457-482.
29. Tanaka K., Zou J.P., Takeda K., Ferrans V.J., Sandford G.R., Johnson T.M., Finkel T., Epstein S.E. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation. 99:1999;1656-1659.
30. Yurochko A.D., Huang E.S. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J. Immunol. 162:1999;4806-4816.
31. Zaia J.A. Pathogenesis of CMV-associated diseases in 1990. Transplant. Proc. 23:1991;1-4.
32. Zhou Y.F., Yu Z.X., Wanishsawad C., Shou M., Epstein S.E. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF β-receptor. Biochem. Biophys. Res. Commun. 256:1999;608-613.